Haleon Commits $12 Million to Expand Panadol Production in Pakistan

Global consumer healthcare leader Haleon has announced a $12 million investment to expand its Panadol production capacity in Pakistan, responding to surging domestic demand for the widely used pain relief medication.

Scaling Up Manufacturing

The investment will fund upgrades at Haleon’s Jamshoro facility, increasing output from 6 billion to 8 billion tablets annually. The expansion includes automated, touch-free packaging systems to meet international quality standards3.

CEO’s Vision

Qawi Naseer, CEO of Haleon Pakistan, emphasized that the company’s 2022 demerger from GSK enabled a sharper focus on consumer healthcare and local innovation. He praised Pakistan’s talent pool and called for long-term economic policies to attract sustained investment4.

Export Ambitions

Haleon plans to export to 19 countries within the next 12–18 months, targeting 10% of total sales from exports. Current export destinations include Vietnam and the Philippines, with further expansion contingent on regulatory approvals.

Policy Support

The move is backed by the Special Investment Facilitation Council (SIFC), whose reforms have improved investor confidence in Pakistan’s pharmaceutical sector. Haleon also commended DRAP for its pro-industry regulatory stance4.